Hapoalim

Hapoalim Securities reports that Vanda Pharmaceuticals (NASDAQ: VNDA) announced that it received a private letter ruling from the IRS stating that Vanda can offset a portion of its taxable income with its full net operating loss carry forwards. “We were previously discounting Vanda's cash position...

Analysts at Hapoalim reiterate their "sell" rating on SunPower Corporation (NASDAQ: SPWRA). The target price for SPWRA is set to $13. Shares of SunPower jumped 22% following its JV announcement with AUO to take over its 1.4GW Fab 3 facility. According to the analysts, “though the deal provides...

Analysts at Hapoalim initiate coverage of Rosetta Resources (NASDAQ: ROSE) with a "hold" rating. The target price for ROSE is set to $24. ROSE gained 3.19% to close at $20.37 yesterday. More Analyst Ratings here

Shares of XenoPort, Inc. (Nasdaq: XNPT) crashed today after the pharmaceutical company received word from the FDA that it would not approve the company's development stage drug called Horizant, which XenoPort developed with partner GlaxoSmithKline Plc (NYSE: GSK). The FDA said that pancreatic tumor...

Hapoalim analyst Jon LeCroy is of the opinion that Arena (NASDAQ: ARNA) is poised to become the next big player in the obesity "prescription mega-market" space. Hapoalim raised Arena’s target to $6.50.